Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 601 - 650 out of 6,220

Document Document Title
WO2005015158A9
The invention relates to compounds that specifically bind a T1R1/T1R3 or T1R2/T1R3 receptor or fragments or subunits thereof. The present invention also relates to the use of hetero-oligomeric and chimeric taste receptors comprising T1R1...  
WO/2005/044787A1
Compounds of formula (I) and salts, solvates, and physiologically functional derivatives thereof, useful for the prophylaxis or treatment of a clinical condition for which a selective β2-adrenoreceptor agonist is indicated, for example ...  
WO/2005/044810A1
&agr -, β-, and &gammad -amino acid derivatives of formula I are disclosed as selective GlyT2 inhibitors for the treatment of central nervous system (CNS) conditions such as muscle spasticity, tinnitus, epilepsy and neuropathic pain. Fo...  
WO/2005/044007A1
A pesticide having stabilized high pesticidal effects for crop plants infected with plant diseases, is presented. The pesticide contains a biphenyl derivative represented by the formula (I) or its salt, as an active ingredient: wherein X...  
WO/2005/044786A1
This invention relates to bicyclic amide, carbamate or urea derivatives and salts thereof which are useful as active ingredients of pharmaceutical preparations. The bicyclic amide, carbamate or urea derivative of the present invention ha...  
WO/2005/044788A1
A process for producing a compound (C) represented by the formula (C) (wherein R1 means hydrogen, C1-6 alkyl, or C3-8 cycloalkyl; and R2 means hydrogen or methoxy), characterized by reacting a compound (A-1) represented by the formula (A...  
WO/2005/041684A2
The present invention relates to the discovery that certain non-naturally occurring, non-peptide arride compounds and amide derivatives, such as oxalamides, ureas, and acrylamides, are useful flavor or taste modifiers, such as a flavorin...  
WO2005000803A8
A process for producing an asymmetric compound (IV), characterized by causing a compound (II) to add a nucleophilic reagent (III) through conjugate addition in the presence of an asymmetric urea compound (I). Also provided is a nonmetall...  
WO/2005/040101A1
The present invention relates to hydroxamate compounds which are inhibitors of histone deacetylase. More particularly, the present invention relates to acylurea/sulfonylurea containing compounds and methods for their preparation. These c...  
WO/2005/040100A1
This invention relates to tetrahydro-naphthalene and urea derivatives and salts thereof which are useful as active ingredients of pharmaceutical preparations. The tetrahydro-naphthalene and urea derivatives of the present invention have ...  
WO/2005/040355A2
The invention provides compounds and methods for inhibition of kinases, such as those of the TAO family, more specifically KIAA1361, TAO, and JIK kinases. The invention provides compounds for modulating protein kinase enzymatic activity ...  
WO/2005/037798A2
The present invention relates to novel compounds, pharmaceutical compositions comprising the same, use of said compounds for the manufacture of a medicament for treatment of pain and disorders related thereto as well as a method for trea...  
WO2005007091A3
One aspect of the invention relates to HDAC inhibitors. Methods of sensitizing a cancer cell to the cytotoxic effects of radiotherapy are also provided. The invention also provides methods for treating cancer and methods for treating neu...  
WO2004062601A3
Antibacterial compounds of formula (I) are provided: As well as stereoisomers, pharmaceutically acceptable salts, esters, and prodrugs thereof; pharmaceutical compositions comprising such compounds; methods of treating bacterial infectio...  
WO/2005/035471A1
An ether derivative represented by the formula (I) or a pharmaceutically acceptable salt, hydrate, or solvate thereof: (I) (wherein the symbols are the same as defined in the description) and an ether derivative represented by the formul...  
WO/2005/033230A2
Low-cure powder coating compositions are disclosed, comprising at least one epoxy-­containing resin and/or at least one siloxane-containing resin, and at least one material having the structure formula (I) wherein R1 is an organic radic...  
WO2004103281A3
One aspect of the invention relates to antagonists of mammalian vanilloid receptors. Another aspect of the invention relates to a method of modulating the activity of a vanilloid receptor in a mammal, comprising administering a compound ...  
WO/2005/028445A2
Compounds of formula (I): wherein A, B and D are each C, N, O or S; E is C or N; the dotted circle within the five-membered ring indicates that the ring may be unsaturated or partially saturated;. R 1 is halogen, hydroxy, C 1-6 álkyl, h...  
WO2005007732A3
Provided herein are polyurea polymers made from an organic isocyanate and a polyamine component, wherein the polyamine component comprises a polyether polyamine in which the nitrogen atoms are secondary. The polyurea polymers of the inve...  
WO2004064730A3
Certain substituted urea derivatives selectively modulate the cardiac sarcomere, for example by potentiating cardiac myosin, and are useful in the treatment of systolic heart failure including congestive heart failure.  
WO2004046162A8
ABSTRACT Potent non-steroidal farnesoid X receptor (FXR) agonists are N-aryl-N-arylmethyl amido and ureido compounds having the chemical structure represented by the following formula (I): INSERT FORMULA wherein E1 is (C1-C8)alkyl, cyclo...  
WO/2005/020899A2
The present application describes modulators of MCP-1 of formula (I) or pharmaceutically acceptable salt forms thereof, useful for the prevention of asthma, multiple sclerosis, artherosclerosis, and rheumatoid arthritis.  
WO/2005/021499A1
The present application describes modulators of MCP-1 of formula (I), or pharmaceutically acceptable salt forms thereof, useful for the prevention of asthma, multiple sclerosis, artherosclerosis, and rheumatoid arthritis.  
WO/2005/019174A1
The present invention is directed to certain hydroxamate derivatives that are inhibitors of histone deacetylase and are therefore useful in the treatment of diseases associated with histone deacetylase activity. Pharmaceutical compositio...  
WO2005000803A3
A process for producing an asymmetric compound (IV), characterized by causing a compound (II) to add a nucleophilic reagent (III) through conjugate addition in the presence of an asymmetric urea compound (I). Also provided is a nonmetall...  
WO/2005/015158A2
The invention relates to compounds that specifically bind a T1R1/T1R3 or T1R2/T1R3 receptor or fragments or subunits thereof. The present invention also relates to the use of hetero-oligomeric and chimeric taste receptors comprising T1R1...  
WO/2005/012231A1
An aminocarbonyl naphthol derivative represented by the formula (1) below and a method for producing the same. (1) (In the formula (1), Y1 and Y2 represent a group selected from the group consisting of aminocarbonyl groups, carboxyl grou...  
WO2004077511A3
The present invention provides novel (meth)acrylic and (meth)acrylamide monomers and polymers produced from those monomers. The monomers of the invention each include only a single vinyl functionality and at least one non-vinyl functiona...  
WO/2005/009940A1
The invention provides novel compounds according to formula I relates to compounds with the general formula I said compounds being useful, e.g. in the treatment of inflammatory, ophthalmic diseases or cancer.  
WO/2005/009944A1
The invention pertains to prodrugs of 9-aminomethyl substituted tetracycline compounds, methods of using the compounds, and pharmaceutical compositions containing them.  
WO/2005/009943A2
The present invention pertains, at least in part, to novel substituted tetracycline compounds. These tetracycline compounds can be used to treat numerous tetracycline compound-responsive states, such as bacterial infections and neoplasms...  
WO/2005/007732A2
Provided herein are polyurea polymers made from an organic isocyanate and a polyamine component, wherein the polyamine component comprises a polyether polyamine in which the nitrogen atoms are secondary. The polyurea polymers of the inve...  
WO/2005/007621A2
This invention describes compounds useful as ubiquitin ligase inhibitors. The compounds of the invention are useful as inhibitors of the biochemical pathways of organisms in which ubiquitination is involved. The invention also provides f...  
WO/2005/007091A2
One aspect of the invention relates to HDAC inhibitors. Methods of sensitizing a cancer cell to the cytotoxic effects of radiotherapy are also provided. The invention also provides methods for treating cancer and methods for treating neu...  
WO/2005/005396A1
Disclosed is a process of making compounds of formula (I) wherein R1, R2, R3, R4 and Ra of formula (I) are defined herein. The product compounds inhibit production of cytokines involved in inflammatory processes and are thus useful for t...  
WO2003102592A3
There is disclosed a method for selectively binding micromolecules having a lysine functionality comprising the steps of: providing a sample containing one or more species of macromolecules, each having a lysine functionality; providing ...  
WO2003084922A8
The invention relates to acyl-4-carboxyphenylurea derivatives, the physiologically-acceptable salts, physiologically-functional derivatives thereof and compounds of formula (I), where the groups have the given meanings, the physiological...  
WO2004087646A3
The invention relates to the compounds of formula (I), wherein W represents N, CR<3>, or a sp<2 >hybridized C atom, E, together with W, represents a 3- to 7-membered saturated carbocylic or heterocyclic ring having 0 to 3 N atoms, 0 to 2...  
WO/2005/000794A1
Compounds of formula (I) wherein R1 to R4, X and A are as defined in the claims and pharmaceutically acceptable salts and esters thereof, are disclosed. The compounds of formula (I) possess utility as tissue-selective androgen receptor m...  
WO/2005/000803A2
A process for producing an asymmetric compound (IV), characterized by causing a compound (II) to add a nucleophilic reagent (III) through conjugate addition in the presence of an asymmetric urea compound (I). Also provided is a nonmetall...  
WO2004002940A8  
WO2003095438A9
Compounds of the formula (I); wherein formula (II) represents a substituted group, an oxa-cycloalkyl group or a thia-cycloalkyl group, are glucokinase activators useful in the treatment of type II diabetes.  
WO/2004/110989A1
This invention relates to novel N-hydroxy-7-(arylamino)heptanamide derivative compounds including salts, carbonates and O-acylated derivatives thereof, pharmaceutical compositions containing such compounds, and the use of those compounds...  
WO2003093250A3
The invention provides compounds of Formula I: (1) these compounds may be in the form of pharmaceutical salts or compositions, may be in pure enantiomeric form or racemic mixtures, and are useful in pharmaceuticals used to treat diseases...  
WO2004078144A3
The present invention relates to Diphenylethylene Compounds and compositions comprising a Diphenylethylene Compound. The present invention also relates to methods for preventing or treating various diseases and disorders by administering...  
WO/2004/106291A1
The present invention provides haloethyl urea compounds as described in Formula (I) and their use as therapeutic agent in the attenuation, inhibition, or prevention of cancer cell migration and cancer cell proliferation.  
WO/2004/106292A1
The present invention provides haloethyl urea compounds as described in Formula (I) and their use as anti-proliferative agent in the attenuation, inhibition, or prevention of non-cancerous cellular proliferation. These compounds are also...  
WO2004026815A3
The present invention is related to a compound of the formula (I), (II), (III), (IV), (V): wherein Z1, Z2, Z3 and Z4 are each and independently selected from the group comprising C(O)-, -C(S)-, -C(O)-NR10-, -C(S)-NR11-, -C(N-CN)-NR12-, -...  
WO/2004/103281A2
One aspect of the invention relates to antagonists of mammalian vanilloid receptors. Another aspect of the invention relates to a method of modulating the activity of a vanilloid receptor in a mammal, comprising administering a compound ...  
WO/2004/101752A2
Novel acyl urea, carbamate, thiocarbamate and related compounds are provided which are effective in inhibiting the cytokine-mediated inflammatory response in cultured cells, in ameliorating bone destruction in an animal model of arthriti...  

Matches 601 - 650 out of 6,220